Impact of COVID-19 on Heart Failure Hospitalization and Outcome in India â?? A Cardiological Society of India Study
- Conditions
- Health Condition 1: I504- Combined systolic (congestive) anddiastolic (congestive) heart failure
- Registration Number
- CTRI/2021/04/032864
- Lead Sponsor
- Cardiological Society of India
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
In this multicentric, retrospective, cross-sectional registry, we plan to retrospectively include consecutive patients presenting with acute HF at various participating hospitals across the Indian states/ union territories during a 6-months period in 2020 (1st of July to 31st December 2020). All cases of acute HF admitted during the corresponding period in the year 2019 will serve as historical controls.The parameters to be studied include type of HF, new-onset or worsening of pre-existing heart failure, clinical characteristics on index admission, risk factors, etiology for heart failure, history previous myocardial infarction, history of previous hospital admissions, treatment received during hospital admission, diagnostic coronary angiography, percutaneous coronary interventions, and coronary artery bypass graft surgery rates.
Patients with a first acute myocardial infarction in the 2 weeks preceding clinical presentation will be excluded. Patients with alternative diagnoses clearly causative of symptoms will also be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To study the change in the number of acute HF admissions in various hospitals in India during the period from 1st of July to 31st December 2020 (COVID-19 era) compared to corresponding period in 2019. <br/ ><br>2.To study in-hospital mortality rates of ADHF admitted to the various hospitals during the COVID-19 era compared to corresponding period in 2019. <br/ ><br>3.To study care of patients with LVAD and Heart transplant during COVID-19 times <br/ ><br>4.To study the benefits of prophylaxis with HCQ/others <br/ ><br>Timepoint: The period from 1st of July to 31st December 2020 (COVID-19 era) compared to corresponding period in 2019
- Secondary Outcome Measures
Name Time Method 1.To find out type of HF (HFpEF vs HFrEF), and rates of guideline directed medical therapy (GDMT), coronary angiography and revascularization in HF patients. <br/ ><br>2.To evaluate the differences in the number of various advanced HF procedures performed in 2020 Vs. 2019 including ICD, CRT, mechanical assist devices and heart transplantation by a survey among the hospitals. <br/ ><br>3.To study the changes in the prescription pattern of ACE inhibitor/ARB/ARNI.Timepoint: The period from 1st of July to 31st December 2020 (COVID-19 era) compared to corresponding period in 2019